

January 2, 2018



## Acasti Pharma to Present at Biotech Showcase Conference

LAVAL, QUÉBEC -- (Marketwired) -- 01/02/18 -- Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Jan D'Alvise, the company's president and chief executive officer will present at Biotech Showcase Conference on Wednesday, January 10 at 11:00 a.m. PT in Yosemite - A of the Ballroom Level. The conference will take place at the Hilton San Francisco Union Square.

A live audio webcast of the presentation will be available under the "News & Investors" section of Acasti's website at [www.acastipharma.com](http://www.acastipharma.com). A replay of the presentation will be available for 60 days following the event.

### ***About Acasti Pharma***

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company's strategy is to initially develop and commercialize CaPre for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit [www.acastipharma.com](http://www.acastipharma.com).

#### Acasti Contact:

Jan D'Alvise

Chief Executive Officer

450-686-4555

[info@acastipharma.com](mailto:info@acastipharma.com)

[www.acastipharma.com](http://www.acastipharma.com)

#### Media Contact:

Jessica Dyas

Canale Communications

619-849-5385

[jessica@canalecomm.com](mailto:jessica@canalecomm.com)

#### Investor Relations Contact:

Glen Akselrod

Bristol Capital Ltd.

905-326-1888 ext 10

[glen@bristolir.com](mailto:glen@bristolir.com)

Source: Acasti Pharma Inc.